Biocure Technology Inc. (BICTF) Stock

About Biocure Technology Inc.

Biocure Technology Inc., along with its subsidiary, is dedicated to the development and market introduction of biopharmaceutical technologies, particularly those leveraging recombinant proteins and ranibizumab. The company's therapeutic pipeline features Interferons-ß, which are being advanced for the treatment of multiple sclerosis. They are also developing Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related ocular condition known as macular edema. Furthermore, Biocure is progressing Filgrastim, a treatment for neutropenia—a deficiency of white blood cells often resulting from cancer, bone marrow transplantation, chemotherapy, or other health issues. Beyond these, Biocure Technology is actively engaged in the research and development of innovative CAR T Cell therapy, intended to pinpoint and destroy cancer cells. Their investigative efforts also encompass a vaccine for foot and mouth disease and a variety of hair growth solutions. Established in 2005, the company's main operations are situated in Vancouver, Canada.

Biocure Technology Inc. is headquartered in CA.

Biocure Technology Inc. (BICTF) stock trades at $0.01 with a market capitalization of $379088. The stock is valued at a price-to-earnings (P/E) ratio of -2.10, price-to-book of 0.18, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $0.07, and currently trades 85.7% below its 52-week high.

On profitability, Biocure Technology Inc. generates a return on equity (ROE) of -6.94%, return on capital employed of -5.77%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.biocuretech.com